IFN-α is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis

Journal of Immunology

Volumn 161, Issue 6, 1998, Pages 2692-2699

  Ferlin Bezombes, Martine ^a   Jourdan, Michel ^a   Liautard, Janny ^a   Brochier, Jean ^a   Rossi, Jean François ^a   Klein, Bernard ^a,b  

^a HÔPITAL SAINT ELOI   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DEXAMETHASONE;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MYELOMA; PLASMA CELL; PRIORITY JOURNAL;

ANTIGENS, CD; APOPTOSIS; CELL SURVIVAL; CYTOKINE RECEPTOR GP130; CYTOKINES; DEXAMETHASONE; HUMANS; INTERFERON-ALPHA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0032530360     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Peest, D., J. Bladé, J. L. Harousseau, B. Klein, A. Österborg, and J. F. San Miguel. 1996. Cytokine therapy in multiple myeloma. Br. J. Haematol. 94:425.
2. Attal, M., F. Huguet, D. Schlaifer, C. Payen, M. Laroche, B. Fournie, B. Mazieres, J. Pris, and G. Laurent. 1992. Intensive combined therapy for previously untreated aggressive myeloma. Blood 79:1130.
3. Wahlin, A., and J. Holm. 1989. Rapid response to recombinant interferon α 2B and high-dose prednisone in multiple drug-resistant multiple myeloma. Eur. J. Haematol. 43:352.
4. Brenning, G., A. Ahre, and K. Nilsson. 1985. Correlation between in vitro and in vivo sensitivity to human leucocyte interferon in patients with multiple myeloma. Scand. J. Haematol. 35:543.
5. Palumbo, A., S. Battaglio, P. Napoli, P. Omede, A. Fusaro, B. Bruno, M. Boccadoro, and A. Pileri. 1994. Recombinant interferon-γ inhibits the in vitro proliferation of human myeloma cells. Br. J. Haematol. 86:726.
6. Jourdan, M., X. G. Zhang, M. Portier, J. M. Boiron, R. Bataille, and B. Klein. 1991. IFN-α induced autocrine production of IL-6 in myeloma cell lines. J. Immunol. 147:4402.
7. Jelinek, D. F., K. M. Aagaard-Tillery, B. K. Arendt, T. Arora, R. C. Tschumper, and J. J. Westendorf. 1997. Differential human multiple myeloma cell line-responsiveness to interferon-α: analysis of transcription factor activation and interleukin 6 receptor expression. J. Clin. Invest. 99:447.
8. Berger, L. C., and R. G. Hawley. 1997. Interferon-β interrupts interleukin-6-dependent signaling events in myeloma cells. Blood 89:261.
9. Klein, B., X. G. Zhang, Z. Y. Lu, and R. Bataille. 1995. Interleukin-6 in human multiple myeloma. Blood 85:863.
10. Jelinek, D. F., G. J. Ahmann, P. R. Greipp, S. M. Jalal, J. J. Westendorf, J. A. Katzmann, R. A. Kyle, and J. A. Lust. 1993. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res. 53:5320.
11. Zhang, X. G., J. P. Gaillard, N. Robillard, Z. Y. Lu, Z. J. Gu, M. Jourdan, J. M. Boiron, R. Bataille, and B. Klein. 1994. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83:3654.
12. Stahl, N., T. J. Farruggella, T. G. Boulton, Z. Zhong, J. E. Darnell, and G. D. Yancopoulos. 1995. Choice of Stats and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 267:1349.
13. Kishimoto, T., S. Akira, M. Narazaki, and T. Taga. 1995. Interleukin-6 family of cytokines and gp130. Blood 86:1243.
14. David, M., G. Zhou, R. Pine, J. E. Dixon, and A. C. Lamer. 1996. The SH2 domain-containing tyrosine phosphatase PTP1D is required for interferon α/β-induced gene expression. J. Biol. Chem. 271:15862.
15. David, M., E. Petricoin, C. Benjamin, R. Pine, M. J. Weber, and A. C. Lamer. 1995. Requirement for MAP kinase (ERK2) activity in interferon α-and interferon β-stimulated gene expression through STAT proteins. Science 269:1721.
16. Liautard, J., R. X. Sun, N. Cotte, J. P. Gaillard, J. C. Mani, B. Klein, and J. Brochier. 1997. Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor. Cytokine 9:233.
17. Gu, Z. J., V. Costes, Z. Y. Lu, X. G. Zhang, V. Pitard, J. F. Moreau, R. Bataille, J. Wijdenes, J. F. Rossi, and B. Klein. 1996. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 88:3972.
18. Wijdenes, J., W. C. Vooijs, C. Clement, J. Post, F. Morard, N. Vita, P. Laurent, R. X. Sun, B. Klein, and J. M. Dore. 1996. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br. J. Haematol 94:318.
19. Horvathova, M., J. P. Gaillard, J. Liautard, C. Duperray, T. Lavabre-Bertrand, P. Bourguard, J. F. Rossi, B. Klein, and J. Brochier. 1995. Identification of Novel and Specific Antigens of Human Plasma Cells by mAb. Oxford University Press, London, p. 713.
20. Vernies, I., C. Haanen, H. Steffens Nakken, and C. Reutelingsperger. 1995. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol Methods 184:39.
21. Lichtenstein, A., Y. P. Tu, C. Fady, R. Vescio, and J. Berenson. 1995. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 162:248.
22. Zhang, X. G., Z. J. Gu, Z. Y. Lu, K. Yasukawa, G. D. Yancopoulos, K. Turner, M. Shoyab, T. Taga, T. Kishimoto, R. Bataille, and B. Klein. 1994. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J. Exp. Med. 179:1337.
23. Juge-Morineau, N., S. Francois, D. Puthier, A. Godard, R. Bataille, and M. Amiot. 1995. The gp 130 family cytokines IL-6, LIF and OSM but not IL-11 can reverse the anti-proliferative effect of dexamethasone on human myeloma cells. Br. J. Haematol. 90:707.
24. Taga, T., and T. Kishimoto. 1997. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol 15:797.
25. Hallek, M., P. Leif Bergsagel, and K. C. Anderson. 1998. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91:3.
26. Egle, A., A. Villunger, M. Kos, G. Bock, J. Gruber, B. Auer, and R. Greil. 1996. Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-α2. Eur. J. Immunol. 26:3119.
27. Fukada, T., M. Hibi, Y. Yamanaka, M. Takahashi-Tezuka, Y. Fujitani, T. Yamaguchi, K. Nakajima, and T. Hirano. 1996. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 5:449.
28. Ogata, A., D. Chauhan, G. Teoh, S. P. Treon, M. Urashima, R. L. Schlossman, and K. C. Anderson. 1997. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol 159:2212.
29. Brenning, G. 1985. The in vitro effect of leucocyte α-interferon on human myeloma cells in a semisolid agar culture system. Scand. J. Haematol 35:178.
30. Einhorn, S., J. O. Fernberg, D. Grander, and R. Lewensohn. 1988. Interferon exerts a cytotoxic effect on primary human myeloma cells. Eur. J. Cancer Clin. Oncol. 24:1505.
31. Schwabe, M., A. T. Brini, M. C. Bosco, F. Rubboli, M. Egawa, J. Zhao, G. L. Princler, and H. F. Kung. 1994. Disruption by interferon-α of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor α-and β-chains. J. Clin. Invest. 94:2317.
32. Mandelli, F., G. Avvisati, S. Amadori, M. Boccadoro, A. Gernone, V. M. Lauta, F. Marmont, M. T. Petrucci, M. Tribalto, M. L. Vegna, F. Dammaco, and A. Pileri. 1990. Maintenance treatment with recombinant Interferon α-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N. Engl. J. Med. 322:1430.
33. Harousseau, J. L. 1997. [Clinical value of interferon-α in the treatment of malignant hematologic diseases. Presse Med. 26:857.
34. Harousseau, J. L., M. Attal, M. Divine, G. Marit, V. Leblond, A. M. Stoppa, J. H. Bourhis, D. Caillot, M. Boasson, J. F. Abgrall, T. Facon, C. Linassier, J. Y. Cahn, T. Lamy, X. Troussard, N. Gratecos, B. Pignon, G. Auzanneau, and R. Bataille. 1995. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the french registry on autologous transplantation in multiple myeloma. Blood 85:3077.
35. Gutterman, J. U. 1994. Cytokine therapeutics: lessons from interferon α. Proc. Natl. Acad. Sci. USA 91:1198.
36. Blade, J., A. Lopez-Guillermo, D. Tassies, E. Montserrat, and C. Rozman. 1991. Development of aggressive plasma cell leukaemia under interferon-α therapy. Br. J. Haematol 79:523.
37. Sawamura, M., K. Murayama, G. Ui, T. Matsushima, J. Tamura, H. Murakami, T. Naruse, and J. Tsuchiya. 1992. Plasma cell leukaemia with α-interferon therapy in myeloma. Br. J. Haematol 82:631.